A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome

Table 3 Number of patients responded to each peptide

Dose of peptide (mg)	Patients	R	T	K	R1	R2	Total	Average*
Dose of peptide (mg)	n	Within 3 courses of vaccinations
0.5	3	2	0	1	1	2	6	2.0
1	3	2	2	1	1	1	7	2.3
3	6	3	4	5	4	3	19	3.2**
3 (cocktail)	6	5	3	4	4	5	21	3.5**

R: RNF43, T: TOMM34, K: KOC1, R1: VEGFR1, R2: VEGFR2.
*: The average numbers of specific CTL induction against each of five peptides per each patient.
**: There was no significant difference to induce the immune responses between the multiple injections of “each peptide” and the single injection of “the peptide cocktail”. (p=0.694, t-test).